目的 探讨缩泉胶囊联合盐酸坦索罗辛缓释胶囊治疗膀胱过度活动症的临床疗效。方法 选取2014年3月-2017年6月上海市青浦区中医院收治的膀胱过度活动症患者105例为研究对象，根据治疗方案不同分为对照组（53例）和治疗组（52例）。对照组清晨饭后口服盐酸坦索罗辛缓释胶囊，0.2 mg/次，1次/d。治疗组在对照组基础上饭后口服缩泉胶囊，1.8 g/次，3次/d。两组患者均连续治疗8周。观察两组的临床疗效，比较两组的排尿指标、膀胱过度活动症症状（OABSS）评分和生活质量评分。结果 治疗后，对照组和治疗组的总有效率分别为84.9%、92.3%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组24 h排尿、尿失禁、尿急、夜晚排尿次数均显著下降，平均尿流量显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组OABSS评分、OAB-q评分均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些评分指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 缩泉胶囊联合盐酸坦索罗辛缓释胶囊治疗膀胱过度活动症具有较好的临床疗效，能改善临床症状，提升生活质量，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Suoquan Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules in treatment of overactive bladder. Methods Patients (106 cases) with overactive bladder in Shanghai Qingpu District Hospital of Traditional Chinese Medicine from March 2014 to June 2017 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into the control group (53 cases) and the treatment group (52 cases). Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules after breakfast, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Suoquan Capsules after meal on the basis of the control group, 1.8 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and urination indexes, OABSS scores, and OAB-q scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.9% and 92.3%, respectively, and there was difference between two groups (P < 0.05). After treatment, the frequency of 24 h urination, urinary incontinence, urgency, and night urination in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, OABSS scores and OAB-q scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Suoquan Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules has clinical curative effect in treatment of overactive bladder, can improve clinical symptoms, and promote the quality of life, with good safety, which has a certain clinical application value.